Cue Biopharma (NASDAQ:CUE – Get Free Report) had its price objective increased by stock analysts at Piper Sandler from $7.00 to $8.00 in a report released on Monday, Benzinga reports. The firm presently has an “overweight” rating on the stock. Piper Sandler’s price target points to a potential upside of 213.73% from the stock’s current price.
Cue Biopharma Stock Performance
CUE opened at $2.55 on Monday. The firm has a market cap of $114.65 million, a price-to-earnings ratio of -2.02 and a beta of 1.97. Cue Biopharma has a 52 week low of $1.70 and a 52 week high of $5.12. The business’s 50 day moving average is $2.27 and its two-hundred day moving average is $3.31. The company has a quick ratio of 3.74, a current ratio of 3.74 and a debt-to-equity ratio of 0.13.
Cue Biopharma (NASDAQ:CUE – Get Free Report) last released its earnings results on Tuesday, August 8th. The company reported ($0.29) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.30) by $0.01. The business had revenue of $1.38 million for the quarter, compared to analyst estimates of $1.21 million. Cue Biopharma had a negative return on equity of 95.36% and a negative net margin of 2,899.44%. On average, research analysts predict that Cue Biopharma will post -1.22 EPS for the current year.
Institutional Trading of Cue Biopharma
About Cue Biopharma
Cue Biopharma, Inc, a clinical-stage biopharmaceutical company, develops injectable biologics to selectively engage and modulate tumor-specific T cells within the body to treat a range of cancers, chronic infectious diseases, and autoimmune diseases. Its lead drug product candidate is CUE-101, a fusion protein biologic designed to target and activate antigen-specific T cells for human papilloma virus-driven cancers.
- Five stocks we like better than Cue Biopharma
- What Does the Consumer Price Index Measure?
- GSK is a remedy for the winter investment blahs
- What Do S&P 500 Stocks Tell Investors About the Market?
- After blowout earnings, Integer may be headed to new highs
- Financial Services Stocks Investing
- Banking and trucking: Is the economy rolling toward troubles?
Receive News & Ratings for Cue Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cue Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.